ATE495749T1 - Zusammensetzung für selektive hemmung der serotoninwiederaufnahme und verfahren dafür - Google Patents

Zusammensetzung für selektive hemmung der serotoninwiederaufnahme und verfahren dafür

Info

Publication number
ATE495749T1
ATE495749T1 AT08720152T AT08720152T ATE495749T1 AT E495749 T1 ATE495749 T1 AT E495749T1 AT 08720152 T AT08720152 T AT 08720152T AT 08720152 T AT08720152 T AT 08720152T AT E495749 T1 ATE495749 T1 AT E495749T1
Authority
AT
Austria
Prior art keywords
composition
serotonin reuptake
extract
relates
reuptake inhibition
Prior art date
Application number
AT08720152T
Other languages
English (en)
Inventor
Sunil Bhaskaran
Mohan Vishwaraman
Original Assignee
Indus Biotech Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indus Biotech Private Ltd filed Critical Indus Biotech Private Ltd
Application granted granted Critical
Publication of ATE495749T1 publication Critical patent/ATE495749T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
AT08720152T 2007-02-12 2008-02-11 Zusammensetzung für selektive hemmung der serotoninwiederaufnahme und verfahren dafür ATE495749T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN255MU2007 2007-02-12
PCT/IN2008/000132 WO2008099426A1 (en) 2007-02-12 2008-02-11 A composition for selective serotonin reuptake inhibition and process thereof

Publications (1)

Publication Number Publication Date
ATE495749T1 true ATE495749T1 (de) 2011-02-15

Family

ID=39402592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08720152T ATE495749T1 (de) 2007-02-12 2008-02-11 Zusammensetzung für selektive hemmung der serotoninwiederaufnahme und verfahren dafür

Country Status (12)

Country Link
US (1) US9669043B2 (de)
EP (1) EP2117560B1 (de)
JP (1) JP5266254B2 (de)
KR (1) KR101183045B1 (de)
CN (1) CN101652143B (de)
AT (1) ATE495749T1 (de)
AU (1) AU2008215743B2 (de)
BR (1) BRPI0806793B8 (de)
CA (1) CA2677872C (de)
DE (1) DE602008004625D1 (de)
ES (1) ES2358306T3 (de)
WO (1) WO2008099426A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154966A1 (en) * 2010-06-10 2011-12-15 Indus Biotech Pvt. Ltd. A method for preparation of highly pure asiaticoside composition from centella asiatica and a method of use thereof
FR2964570A1 (fr) * 2010-09-09 2012-03-16 Burgundy Procede de preparation d'un extrait de centella asiatica
CN101983966B (zh) * 2010-11-19 2012-08-15 浙江大学 低积雪草苷含量总苷出发同时制备积雪草苷和羟基积雪草苷的工艺
WO2012164356A1 (en) 2011-06-02 2012-12-06 Indus Biotech Private Limited A method of managing hypercortisolemia, headache disorders, neuropathic pain and related disorders
MX2019000769A (es) * 2016-07-17 2019-09-19 Oneness Biotech Co Ltd Formulacion topica para promover la curacion de heridas.
CN108002997B (zh) * 2017-12-15 2020-10-23 中国医学科学院药用植物研究所海南分所 一种具有止呕作用的沉香提取物及其应用
CN111329866B (zh) * 2020-04-12 2023-04-07 云南民族大学 一种五环三萜类化合物在制备抗偏头痛药物中的应用
WO2021241876A1 (ko) 2020-05-29 2021-12-02 재단법인 대구경북첨단의료산업진흥재단 카복사미드 유도체 및 이를 유효성분으로 함유하는 정신질환의 예방 또는 치료용 약학적 조성물
EP4159718A4 (de) 2020-05-29 2023-10-04 Daegu-Gyeongbuk Medical Innovation Foundation Sulfonamidderivat und pharmazeutische zusammensetzung damit als wirkstoff zur vorbeugung oder behandlung von psychischen erkrankungen
CN116057053A (zh) 2020-05-29 2023-05-02 大邱庆北尖端医疗产业振兴财团 含至少一个n的5元杂芳基衍生物和含其为活性成分用于预防或治疗精神障碍的药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383171A3 (de) 1989-02-11 1991-07-24 Hoechst Aktiengesellschaft 2,3,23-Trihydroxy-urs-12-en Derivate zur Behandlung von Kognitiven Störungen
KR100228873B1 (ko) * 1997-03-24 1999-11-01 강재헌 센텔라아시아티카에서 분리한 아시아티코사이드와 마테카소 사이드의 수용성 추출물을 함유한 간세포 및 항간섬유화 치료제
JP4497566B2 (ja) * 1998-09-02 2010-07-07 株式会社 日本薬用食品研究所 アルドース還元酵素阻害剤並びに新規サポニン及び新規サポゲノール
CN1211098C (zh) * 2001-05-29 2005-07-20 中国人民解放军第二军医大学 积雪草总甙抗抑郁症的用途
JP2004002335A (ja) * 2002-03-28 2004-01-08 Ortho Corporation 不定愁訴症状改善剤及び食品とその組成物
CN1121862C (zh) * 2002-04-16 2003-09-24 中国人民解放军第二军医大学 羟基积雪草甙用于制备治疗抑郁症药物的用途
FR2848117B1 (fr) * 2002-12-10 2006-08-04 Roche Consumer Health Ltd Procede de preparation d'un extrait de centella asiatica riche en madecassoside et en terminoloside
CN100467025C (zh) * 2004-06-09 2009-03-11 北京苏里曼医药科技有限公司 积雪草总苷、积雪草苷或羟基积雪草苷在制备防治心、脑血管疾病药物中的用途
CN1583127A (zh) 2004-06-11 2005-02-23 张正生 一种治疗抑郁症和肿瘤的中药制剂及其制备方法
CN100441201C (zh) 2005-06-08 2008-12-10 浙江省医学科学院 含积雪草水溶性有效组分的中药缓释制剂及其制备方法

Also Published As

Publication number Publication date
ES2358306T3 (es) 2011-05-09
BRPI0806793A2 (pt) 2011-09-13
DE602008004625D1 (de) 2011-03-03
JP5266254B2 (ja) 2013-08-21
KR101183045B1 (ko) 2012-09-20
US20080194499A1 (en) 2008-08-14
JP2010530841A (ja) 2010-09-16
EP2117560A1 (de) 2009-11-18
AU2008215743A1 (en) 2008-08-21
CN101652143B (zh) 2013-11-06
KR20090117736A (ko) 2009-11-12
US9669043B2 (en) 2017-06-06
CA2677872C (en) 2012-04-03
WO2008099426A1 (en) 2008-08-21
BRPI0806793B1 (pt) 2021-03-09
CN101652143A (zh) 2010-02-17
EP2117560B1 (de) 2011-01-19
AU2008215743B2 (en) 2010-10-07
BRPI0806793B8 (pt) 2021-05-25
CA2677872A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
ATE495749T1 (de) Zusammensetzung für selektive hemmung der serotoninwiederaufnahme und verfahren dafür
BRPI0715018A2 (pt) Extrato derivado de cana de açúcar, produto alimenticio, preparação para uso como produto farmacêutico,cosmético, processo de produção de extratos derivados de cana de açúcar e método de refino de um extrato fitoquímico
WO2009088838A3 (en) Triarylmethane analogs and their use in treating cancers
WO2009093255A3 (en) A new nutraceutical composition from garcinia mangostana
CL2007003346A1 (es) Compuestos derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome de abstinencia a una sustancia, tras
HRP20200278T1 (hr) Ekstrakti chelidonium majus i njihova uporaba u liječenju kožnih poremećaja i poboljšanju regeneracije kože
Dereli et al. Discovery of new antidepressant agents: In vivo study on Anthemis wiedemanniana Fisch. & Mey
TW200740447A (en) Pharmaceutical composition for treating inflammation, pain, arthritis and spinitis, and proliferating osteoblastic cell and method thereof
CN108653368A (zh) 一种珊瑚树萜类成分的制备方法
CN104815002A (zh) 一种宽筋藤提取物的获得方法及其应用
Su et al. Studies on chemical constituents from stems and leaves of Adenanthera pavanina
Jaliwala et al. In vitro anthelmintic activity of aerial parts of Argemone mexicana Linn
Rodrigues-Torres et al. Phytochemical investigation, antinociceptive activity and cytotoxicity of crude extracts of Calea uniflora Less.
EP1907380A4 (de) Verfahren zur gewinnung synthetischer und halbsynthetischer lignanderivate, deren antiparasitäre wirkungen und entsprechende pharmazeutische formulierungen, einschliesslich des therapeutischen verfahrens, bei dem dieses lignan zur behandlung von parasitose verwendet wird
MX2014010926A (es) Composicion herbaria para el tratamiento de transtornos metabolicos.
Jiang Study on chemical constituents of Lonicera japonica bud
Choi et al. Ameliorating effect of balloon flower saponin on the ethanol‐induced memory impairment in mice
CN102188465A (zh) 一种常春藤属植物提取物的制备方法及其用途
ES2324584B1 (es) Formulacion farmaceutica para el tratamiento del sindrome de inmunodeficiencia humana (sida) y procedimiento de obtencion de dicha formulacion.
BRPI1006987A2 (pt) extrato de cissampelos pareira, uso do mesmo, processo para o preparo do mesmo, fração, composição farmacêutica e método para o tratamento de infecção pelo vírus da dengue.
Gerelt-Od et al. Alkaloids from Sedum telephium L.
CN105985402B (zh) 一种甾醇内酰胺化合物马勃内酰胺及其在制备抗补体药物中的用途
EP1732875B1 (de) Verfahren zur isolierung des lebenschützenden mittels oleanolsäure aus lantana camara
NZ702155A (en) Novel pharmacological use of cimicifuga extract
Govind Protective effect of Nerium indicum on ccl4 induced hepatotoxicity in rat

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties